杰拉尼尔杰拉诺酸和MAOB-CYP3A4轴:一种代谢转移,是与年龄相关的肝癌风险的基础
1Nutritional Biochemistry, Faculty of Wellness Studies, Department of Nutritional Health, Kwassui Women's University, Nagasaki, Japan.
Frontiers in aging
|October 27, 2025
概括
由于单胺氧化酶B (MAOB) 活性降低,Geranylgeranoic acid (GGA) 水平随着年龄的增长而降低. 细胞染色体P450 3A4 (CYP3A4) 可能会补偿,提供关于肝脏衰老和癌症预防的见解.
科学领域:
- 生物化学 生化学
- 肝病学 肝病学是一种肝病学.
- 老年学是指老年学的学科.
背景情况:
- 格拉尼尔日拉诺酸 (GGA) 是一种非循环的异烯酸,具有针对肝细胞癌的化学预防性.
- 哺乳动物内源性GGA合成主要依赖于由单氨酸氧化酶B (MAOB) 氧化兰.
- 与年龄相关的MAOB活性下降导致肝脏GGA水平降低,可能影响肝脏健康.
研究的目的:
- 审查目前关于老年肝脏中GGA生物合成和代谢的研究结果.
- 研究MAOB-CYP3A4轴在肝脏衰老和GGA产生中的作用.
- 探索这些代谢途径与年龄相关的肝功能障碍和肝癌发生的相关性.
主要方法:
- 关于GGA代谢和肝脏衰老的研究文献综述.
- 在GGA合成中MAOB-CYP3A4酶轴的分析.
- 检查肝脏代谢途径的年龄相关变化.
主要成果:
- MAOB是内源GGA合成的主要酶,但其活性随着年龄的增长而减弱.
- 细胞染色体P450 3A4 (CYP3A4) 作为MAOB缺乏条件下GGA生产的潜在补偿途径出现.
- 在GGA代谢中MAOB和CYP3A4之间的相互作用对于理解肝脏衰老至关重要.
结论:
- 该CYP3A4-GGA途径为与年龄相关的MAOB活性下降提供了补偿机制.
- 了解这种酶轴可以阐明肝脏衰老的复杂性.
- 向CYP3A4-GGA途径可能为预防与年龄相关的肝癌发生提供策略,特别是在老年人中.
相关概念视频
01:18Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Metabolism
194
Geriatric patients show significant variation in how their bodies process medications, which can change how effective and safe treatments are. The liver is the primary organ where drug metabolism occurs, involving two main types of chemical reactions: phase I and II. Phase I metabolism is driven by the cytochrome P450 enzyme system, which includes key types such as CYP3A, CYP2D6, and CYP2C9. Research indicates that while aging doesn't notably alter the levels or activity of these enzymes, it...
194
01:27Pharmacodynamics in Geriatric Patients: Effects of Age
183
Age-related pharmacokinetic changes are extensively documented, but understanding age-related pharmacodynamic alterations is relatively limited. This knowledge gap can be partly attributed to the complexity of developing appropriate measures of drug responses compared to bioanalytical methods for determining drug concentrations.Most information regarding age-related differences in human pharmacodynamics originates from cross-sectional studies. However, these studies assume that observed mean...
183
01:22Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Absorption
223
As individuals age, their body's physiology evolves, affecting drug pharmacokinetics. The most apparent changes occur in the gastrointestinal tract, where an increase in gastric pH, a delay in gastric emptying, and a reduction in gastrointestinal motility are observed. Remarkably, these changes do not substantially modify the absorption of orally administered drugs, particularly those absorbed via passive diffusion.Transdermal drug delivery emerges as a highly viable method for older adults due...
223
01:18Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Excretion
232
In geriatric patients, renal physiology undergoes significant changes, including diminished renal blood flow and a lower glomerular filtration rate (GFR), leading to alterations in medication clearance. Drugs such as aminoglycoside antibiotics, lithium, and digoxin, which rely on glomerular filtration for removal from the body, particularly impact pharmacokinetics. These drugs tend to have slower clearance rates in older adults, necessitating careful dosage considerations.Evaluation of renal...
232
01:00Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Distribution
227
Drug distribution in the human body is influenced by several factors, including plasma protein concentration, body composition, blood flow, tissue-protein concentration, and tissue fluid pH. Among these, changes in plasma protein concentration and body composition due to aging significantly affect how drugs are distributed within the body. Specifically, aging is associated with a decrease in albumin levels by about 10% and an increase in α1-acid glycoprotein levels. These alterations are...
227
01:08Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment
248
Hepatic impairment, characterized by decreased liver function, does not uniformly mandate adjustments in drug dosage. Whether dosage modifications are necessary depends on various factors related to the drug's metabolism and elimination pathways. If a drug is primarily excreted via the kidneys and bypasses significant hepatic processing, if it undergoes minimal metabolic transformation in the liver, or if it is volatile and primarily expelled through the lungs, dose adjustments may not be...
248